[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594214":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":18,"collaborators":10,"id":22,"slug":23,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":27,"acronym":10,"eligibilityCriteria":28,"healthyVolunteers":29,"sex":30,"minAge":31,"maxAge":10,"enrollmentInfo":32,"targetDuration":10,"studyType":35,"phases":10,"briefSummary":36,"conditions":37,"keywords":10,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":10},{"fullName":5,"class":6},"Sohag University","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"control group \"normal\"",null,"normal individuals",{"label":13,"type":10,"description":14,"interventionNames":10},"case group 1 \"patients with lower GIT symptoms suggestive of irritable bowel syndrome\"","those who fulfill the criteria of irritable bowel disease.no intervention needed.",{"label":16,"type":10,"description":17,"interventionNames":10},"case group 2 \"patients with lower GIT symptoms suggestive of inflammatory bowel disease\"","those with bloody diarrhea or chronic diarrhea or other manifestations suggest inflammatory bowel disease.no intervention needed.",{"type":19,"investigatorFullName":20,"investigatorTitle":21,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Rania Mohammad Abd-ellatif","Internal medicine resident","100594214","diagnostic-study-for-differentiating-functional-from-organic-diseases-in-patients-with-lower-git-symptoms-100594214",false,"NCT07016529","Diagnostic Study for Differentiating Functional From Organic Diseases in Patients With Lower GIT Symptoms","Diagnostic Utility of Myeloperoxidase for Differentiating Irritable Bowel Syndrome From Inflammatory Bowel Disease in Patients With Lower GIT Symptoms","Inclusion Criteria:\n\n* Adults (≥18 years) presenting with chronic lower gastrointestinal symptoms, such as diarrhea, abdominal pain, or altered bowel habits, for a duration exceeding 6 weeks.\n* Patients with no prior diagnosis of IBD or IBS.\n* Patients willing to provide informed consent and comply with study requirements.\n* Those without recent use of immunosuppressants or anti-inflammatory medications that could affect biomarker levels\n\nExclusion Criteria:\n\n* Patients with a confirmed diagnosis of IBD and currently on treatment.\n* Those with acute gastroenteritis, infectious colitis, or positive stool cultures for pathogens.\n* Patients diagnosed with colorectal cancer, celiac disease, or other known organic GI disorders.\n* Recent antibiotic, NSAID, or corticosteroid use within the past 4 weeks.\n* Pregnant or lactating women.",true,"ALL","18 Years",{"count":33,"type":34},100,"ESTIMATED","OBSERVATIONAL","The study is intended to find a new trusted, cost-effective biomarker for differentiating irritable bowel syndrome from inflammatory bowel disease to decrease the use of unnecessary invasive methods in patients with irritable bowel syndrome",[38,39],"Irritable Bowel Syndrome (IBS)","Inflammatory Bowel Disease (IBD)","NOT_YET_RECRUITING","2025-06-04",{"date":43,"type":44},"2025-06-11","ACTUAL",{"date":46,"type":34},"2025-06-10",{"date":48,"type":34},"2025-12-20",{"name":5,"class":6}]